This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Astrana Health (ASTH) and Baxter International (BAX)

Tipranks - Tipranks - Tue May 19, 9:48PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM), Astrana Health (ASTH) and Baxter International (BAX).

Claim 55% Off TipRanks

Insmed (INSM)

Truist Financial analyst Danielle Brill maintained a Buy rating on Insmed yesterday and set a price target of $185.00. The company’s shares closed last Monday at $107.15.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 13.3% and a 53.1% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Rapport Therapeutics, Inc., and Centessa Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $200.88 average price target, an 87.1% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $205.00 price target.

See the top stocks recommended by analysts >>

Astrana Health (ASTH)

In a report released yesterday, Jailendra Singh from Truist Financial maintained a Buy rating on Astrana Health, with a price target of $47.00. The company’s shares closed last Monday at $38.98.

According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.7% and a 35.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Currently, the analyst consensus on Astrana Health is a Strong Buy with an average price target of $41.57, implying an 8.7% upside from current levels. In a report issued on May 8, TipRanks – Google also upgraded the stock to Buy with a $40.00 price target.

Baxter International (BAX)

The company’s shares closed last Monday at $17.79.

According to TipRanks.com, Jennings is ranked 0 out of 5 stars with an average return of -2.4% and a 40.4% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Baxter International with a $21.14 average price target, which is a 21.5% upside from current levels. In a report issued on May 8, Argus Research also maintained a Hold rating on the stock.

Read More on INSM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).